Request that the FDA issue guidance to ensure truthful and non-misleading communications by sponsors concerning the safety and effectiveness of biosimilars, including interchangeable biologics, relative to reference product(s).

1 organizations filed 1 public comment on Request that the FDA issue guidance to ensure truthful and non-misleading communications by sponsors concerning the safety and effectiveness of biosimilars, including interchangeable biologics, relative to reference product(s)., at the Food and Drug Administration. The comment window closed 2712d ago.

Commenters (1)

• Association for Accessible Medicinestrade assoc.

  1 filing · confidence 97%